6.92 USD
↘ 1.16 (14.40%)AT CLOSE (11:59 AM EDT)
Corbus Pharmaceuticals Holdings, Inc.
CRBPNASDAQ • USD
6.88
↘ 0.04 (0.59%)
POST MARKET (AS OF 07:52 PM EDT)
Post Market
AS OF 07:52 PM EDT
6.88
↘ 0.04 (0.59%)
Market: CLOSED
Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) are trading at $6.93. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest CRBP is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 15, 2026.
Open?$8.08
High?$8.08
Low?$6.33
Prev. Close?$8.08
Volume?3.8M
Avg. Volume?986.8K
VWAP?$6.75
Rel. Volume?3.81x
Bid / Ask
Bid?$6.86 × 3.8K
Ask?$6.96 × 600
Spread?$0.10
Midpoint?$6.91
Valuation & Ratios
Market Cap?133.8M
Shares Out?18.7M
Float?15.9M
Float %?89.7%
P/E Ratio?N/A
P/B Ratio?1.31
EPS?-$5.27
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Themes
Employees
36
Market Cap
156.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-10-24
Address
500 RIVER RIDGE DRIVE
NORWOOD, MA 02062
Phone: 617-963-0103
NORWOOD, MA 02062
Phone: 617-963-0103
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?60
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.34Distress
Confidence?51%Low
Short InterestHigh
Short % of Float?14.12%High
Short Interest?2.2M
Days to Cover?3.7
Free Float15.9M
Avg Daily Volume611.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?5.71Strong
Quick Ratio?5.71Strong
Cash Ratio?1.09Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.31CHEAP▾
Peers100
S&P91
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-99.7%WEAK▾
S&P3
ROA?-80.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-86687000
Enterprise Value?$110.5M
Fundamentals ratios updated end of day